Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX-Reference-Cited by-同舟云学术

Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX

Published:2024 Issue:9 Volume:15 Page:3372-3381
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Morgan Katherine A.¹^ORCID,Wichmann Christian W.²³⁴^ORCID,Osellame Laura D.²³^ORCID,Cao Zhipeng²³^ORCID,Guo Nancy²,Scott Andrew M.²³⁴⁵^ORCID,Donnelly Paul S.¹^ORCID

Affiliation:

1. School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia

2. Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia

3. School of Cancer Medicine, La Trobe University, Melbourne, Australia

4. Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia

5. Department of Medicine, University of Melbourne, Melbourne, Australia

Abstract

Alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX leads to a highly significant therapeutic response in a mouse xenograft model.

Funder

Australian Research Council

Cancer Council Victoria

Australian Cancer Research Foundation

National Health and Medical Research Council

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/SC/D3SC06365H

Reference63 articles.

1. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

2. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy

3. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

4. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging

5. Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours